Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Paradigm Biopharmaceuticals
Its shares trade on ASX under the ticker PAR.AX. It has been listed since 19 August 2015. In the fiscal year to 30 June 2025, it reported revenue of A$7.1m and a net loss of A$18.8m. At that date it held total assets of A$24.6m and shareholders' equity of A$21.2m.
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The company is engaged in researching and developing therapeutic products for human use. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). The company develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Aug 2015
- Website
- paradigmbiopharma.com ↗
Leadership
Pay as last reported
- Mr. Paul RennieExecutive Chairman of the Board, Managing Director, since 2014A$1.1m
- Ms. Abby NivenChief Financial Officer, Company Secretary
- Mr. Matthew FryNon-Executive Independent DirectorA$80,000
- Mr. Amos MeltzerNon-Executive Independent DirectorA$89,200
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 33
- Social
- 55
- Governance
- 13
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Paradigm Biopharmaceuticals Ltd focuses on injectable pentosan polysulfate sodium for osteoarthritis treatment.
- Zilosul is the brand name for PPS, which mimics glycosaminoglycans to treat joint issues.
- The company develops PPS for multiple conditions including mucopolysaccharidoses and alphavirus-induced arthralgia.
Weaknesses
- The company's focus on a single product, iPPS/PPS, limits diversification.
- Paradigm Biopharmaceuticals Ltd has no other therapeutic products in development.
- The company's research is limited to specific conditions like osteoarthritis and MPS.
Opportunities
- Expanding PPS treatment to chronic heart failure and acute respiratory distress syndrome offers new markets.
- The use of PPS for alphavirus-induced arthralgia presents a growing market opportunity.
- Developing PPS for joint function, mobility, and pain could increase patient base.
Threats
- The company's reliance on a single product increases vulnerability to market changes.
- Regulatory approval delays could impact PPS development timelines.
- Competition from other biopharmaceutical companies may affect market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.